Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.60 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.60 |
| ▸ | CHRNG | P07510 | 2/20 | 0.60 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.60 |
| ▸ | CHRND | Q07001 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104239 | 0.87 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL633270 | 0.85 | TSHR (0.53) | SLC6A2SLC6A4SLC6A3HPGDALDH1A1 | |
| SCHEMBL10026169 | 0.83 | ALDH1A1 (0.49) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL786551 | 0.81 | SMN1; SMN2 (0.51) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL21331278 | 0.80 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL18527134 | 0.77 | ALDH1A1 (0.44) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL11674176 | 0.77 | HPGD (0.51) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL2924706 | 0.77 | HPGD (0.54) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL633275 | 0.76 | CHRNA1 (0.62) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL10728309 | 0.76 | KDM4E (0.52) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| EP-3793559-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| CN-112469412-A | Substituted dihydropyrazolopyrazine carboxamide derivatives | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| EP-2419400-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7910740-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2155740-B1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-01-26 | — | — | EP | disclosed |
| WO-2008138753-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-11-15 | — | — | US | disclosed |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | QDPR, SIRT5, PDXK | SLC6A2 4304/4885SLC6A4 3600/4885SLC6A3 3833/4885 |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | SLC6A2 844/4885SLC6A4 1155/4885SLC6A3 364/4885 |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | SLC6A2 844/4885SLC6A4 1155/4885SLC6A3 364/4885 |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | SLC6A2 844/4885SLC6A4 1155/4885SLC6A3 364/4885 |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | SLC6A2 844/4885SLC6A4 1155/4885SLC6A3 364/4885 |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | APP, BACE1, BACE2 | SLC6A2 1165/4885SLC6A4 2720/4885SLC6A3 2735/4885 |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | SLC6A2 844/4885SLC6A4 1155/4885SLC6A3 364/4885 |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | SLC6A2 844/4885SLC6A4 1155/4885SLC6A3 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.